Fingolimod Capsule
Product Images NDC 68462-166

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Fingolimod (NDC 68462-166). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure.jpg (Structure)

Structure.jpg (Structure)
Chemical structure diagram of fingolimod depicting its molecular components including a benzene ring, hydroxy groups, an ammonium ion, and a chloride ion.*
FDA Label Image

Blistercarton7cap (Blistercarton7cap)

Blistercarton7cap (Blistercarton7cap)
Fingolimod Capsules 0.5 mg oral dosage form packaging label from Glenmark Pharmaceuticals Inc., USA. The carton contains 7 capsules (1 x 7 unit-dose) with child-resistant packaging and instructions for use. The label highlights the 0.5 mg strength multiple times and includes storage instructions and manufacturer details.*
FDA Label Image

Bottlelabel (Bottlelabel)

Bottlelabel (Bottlelabel)
Fingolimod Capsules 0.5 mg oral dosage form label by Glenmark Pharmaceuticals Inc., USA. The label indicates a 30 tablets package and includes storage instructions, pharmacist dispensing guidance, manufacturer details, and a barcode. The product is prescription only.*
FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
A line graph comparing the percentage of patients with three-month confirmed progression over time (days) between two treatment groups: Fingolimod 0.5 mg and placebo. The X-axis represents time in days, and the Y-axis shows the percentage of patients. The placebo group shows a higher progression percentage (24%) compared to the fingolimod group (18%) at the end of the study period (720 days).*
FDA Label Image
FDA Label Image

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.